Kiora Pharmaceuticals (KPRX) Q4 2024 earnings summary

Executive summary

• Advanced two key retinal disease drug candidates, KIO-104 and KIO-301, into Phase 2 clinical trials with approvals to initiate KLARITY and ABACUS-2 studies in 2025.

• Received $3.3 million in reimbursed R&D expenses from Laboratoires Théa for KIO-301 development, supporting capital efficiency.

• Ended 2024 with $26.8 million in cash and short-term investments, providing operational runway into 2027, beyond expected 2026 data readouts.

Financial highlights

• Net income for 2024 was $3.6 million, a turnaround from a net loss of $12.5 million in 2023, driven by $16 million in collaboration revenue.

• Fourth quarter 2024 net loss was $4.2 million, compared to $2.3 million in Q4 2023.

• R&D expenses for 2024 were $7.8 million before $2.9 million in reimbursed credits; G&A expenses were $5.5 million, up from $4.7 million in 2023.

• Total revenue for 2024 was $16.02 million, primarily from collaboration revenue.

• Cash, cash equivalents, and short-term investments totaled $26.8 million at year-end 2024.

Outlook and guidance

• Cash and short-term investments expected to fund operations into 2027, excluding potential partnership milestones.

• Data readouts from KLARITY and ABACUS-2 Phase 2 trials anticipated in 2026.

• Net R&D expenses projected to increase in 2025 due to patient enrollment in KLARITY; G&A expenses expected to remain stable.